Certainty: A virtual twin of cellular immunotherapy for personalized cancer treatment
The Certainity project, launched on December 1, 2023, aims to develop a “virtual twin” in cancer immunotherapy, particularly for CAR T-cell treatments. This digital model integrates a patient’s clinical, molecular and cellular data to simulate disease progression and treatment options, with an initial focus on multiple myeloma. The EU-funded CERTAINTY project, led by Fraunhofer IZI, combines big data, machine learning and computer models to personalize cancer treatment. The project also takes socio-economic factors into account and prioritizes data protection.
Partners of the project:
- Fraunhofer-Gesellschaft, Germany
-
- Fraunhofer IZI (project coordination)
- Fraunhofer SCAI
- Fraunhofer IMW
- University of Leipzig Medical Center, Germany
- Singleron Biotechnologies GmbH, Germany
- Collaborate Project Management, Germany
- Myeloma Patients Europe AISBL, Belgium
- TriNetX Oncology GmbH, Germany
- Masaryk University, Czech Republic
- Information Technology for Translational Medicine, Luxembourg
- University Hospital of Würzburg, Germany
- Institut Curie, France
- University of Namur, Belgium
- Universitair Medisch Centrum (UMC) Utrecht, The Netherlands
- Charité – Universitätsmedizin Berlin, Germany
- European Society for Blood and Marrow Transplantation (EBMT), The Netherlands
- HealthTree Foundation, USA
- Roche Pharma AG, Switzerland
Back to News